Johnson & Johnson (J&J) has been under fire for a decade for a myriad of cases alleging that its talc-based baby powder has caused cancer. But the company says it’s moving forward in trying to fix this longstanding issue.
In a meeting at the New York Stock Exchange on Tuesday, J&J (JNJ) – Get Free Report in-house lawyer Eric Haas told investors that the company has made “progress” in the last few weeks by “resolving” some of the cases it’s facing, according to a report by Bloomberg.
Related: ‘Buy Now, Pay Later’ is more popular, and riskier, than ever
Bloomberg reported that there have been agreements reached on about 100 cases with three different law firms, though the finances of any of the deals were undisclosed. J&J is facing over 50,000 cases that claim it hid the cancer risk that comes with using its baby powder.
Joaquin Duato, J&J’s chief executive officer, also told investors that the pharmaceutical company wants to “bring resolution” to the cases so it can focus more on advancing treatment for patients.
Related: Uber, DoorDash forced to pay up big due to new rule
The company has tried twice and been rejected by the New Jersey courts to use bankruptcy in order to build a trust to pay its victims through a $9 billion settlement.
J&J has continued to claim that its talc-based powder does not come with a cancer risk despite pulling its talc-based powders from the U.S. market in 2020. The company said it will pull talcum powder worldwide by the end of 2023.
Investing can be hard. We make it easier. There are thousands of stocks you can invest your hard-earned money in. Our pros help you decide what stocks to buy and when to buy them. Sign up to find out what stocks we’re buying now (XYZ isn’t one of them!)
